PrimeStreet Capital highlights that the global economy continues to face mounting risks and signs of slowdown. In response, the firm urges investors to diversify portfolios and align with key megatrends to build sustainable wealth. Over the past 2.5 years, its Global Venture Capital Fund has generated a 7x growth in NAV-MOIC and achieved an IRR of 180%. One of its key portfolio companies, Novel Immunologic Therapy for Neurodegenerative Diseases, is currently awaiting FDA approval for a groundbreaking ALS (Amyotrophic Lateral Sclerosis) treatment. Several major Japanese pharmaceutical companies are now in talks to secure licensing and distribution rights in Asia, positioning the product for strong regional market penetration.
Mr. VIRIT VICHITVADAKAN, Co-Founder and Partner of PrimeStreet Capitalone of Thailand's leading global venture capital firms under PrimeStreet Groupstated that the global economy is showing sustained signs of deceleration due to multiple factors, including trade uncertainty, global tariff increases by the U.S., inflationary pressure, and geopolitical tensions, especially in the Middle East. These risks have severely impacted energy prices and investor confidence worldwide.
"Crises often bring hidden opportunitiesespecially in the investment world, where downturns present chances to acquire quality assets at attractive prices," Mr. VIRIT said. "Investors need to pivot their strategies, emphasizing diversification into high-potential assets, especially those with low correlation to traditional marketssuch as alternative assets including Private Equity (PE) and Venture Capital (VC), particularly within megatrend sectors."
According to 25-year historical data from Cambridge Associates, these asset classes have generated an average annual return of 23.1% with lower volatility than many traditional investments.
The Global Venture Capital Fund managed by PrimeStreet Capital, now in its third year, focuses on four primary megatrend themes:
- Healthcare and Wellness
- Environment and Infrastructure
- Impact Technology
- Food, Water, and Natural Resources
The fund has achieved over 7x growth in Net Asset Value (NAV), with an unrealized MOIC (Multiple on Invested Capital) close to 7x and an IRR of 180%significantly outperforming the global 3-year VC IRR average of approximately 20.2%, according to Pitchbook's global performance data.
Looking ahead to the second half of 2025 and into 2026, PrimeStreet Capital remains focused on these four megatrend pillars through targeted investments in four core companies. Among them is Novel Immunologic Therapy for Neurodegenerative Diseases, a biotech firm currently in the final stages of FDA approval for a new ALS treatment. The drug has already passed initial approval phases and is undergoing final efficacy testing with over 300 patients across the U.S., Europe, and Japan.
Notably, several major Japanese pharmaceutical companies have expressed strong interest in negotiating licensing deals for the manufacturing and distribution rights of the ALS treatmentindicating strong commercial potential in the Asian market. This opportunity is expected to deliver outsized returns in a fraction of the time typically seen in the biotech sector, where development and commercialization often span over a decade.
"We aim to begin distributing returns to investors within 2-3 years and close the fund by year 5 or 6well ahead of industry averages," said Mr.VIRIT. "Our commitment remains firm: to generate profits while delivering systemic benefits, in line with our philosophy of 'bringing global innovations home for Thailand's benefit.' We strive to collaborate with Thailand's public health sector and local businesses to uplift the nation's infrastructure in a sustainable way."